BioNTech SE – ADR (NASDAQ:BNTX) stock is back in action after a sudden fall last week when the stock fell as much as 20% from Tuesday through Thursday.
However, since the stock fell without any news, investors rushed to buy the dips and the stock went up 9.35% on Friday to close at $183.71.
Moreover, as per the early signal, the stock is all set to gap up by another 10% to above the $200 mark.
BNTX stock is already up by a whopping 114% year-to-date as investors continue to bet on the company’s future with relation to its partnership with Pfizer where the company has reached deals to supply their COVID-19 vaccine to Canada and Israel beyond 2021.
Thir morning, the company reported earnings of €4.39 per share in the first quarter, may not be comparable to the S&P Capital IQ Consensus of €1.95
Revenues during the quarter grew 7,294.9% year-over-year to €2.05 billion, compared to the €1.4 billion S&P Capital IQ Consensus.
More than 450 million doses of BNT162b2 supplied to 91 countries or territories worldwide as of May 6, 2021.
FY21 Guidance: Sees R&D expenses of €750 million–€850 million and Capital Expenditures of €175 million — €225 million.
There areother couple of important updates this morning from Pfizer. Firstly, Pfizer (PFE) to provide 1.8 billion coronavirus vaccine doses to EU, and secondly Brazil wants deal with Pfizer (PFE) for 100 million coronavirus vaccines.
Moreover, BioNTech announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for south east Asia in Singapore.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.